Accessibility Menu
Chemomab Therapeutics logo

Chemomab Therapeutics(NASDAQ) CMMB

Market Cap$11.16MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-99%
5 Year-98%
1 Year-64%
1 Month-9%
$1.55
+1.31%
+0.02Today
After hours$1.55+$0.00 (+0.00%)
Chemomab Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 1.552026-07-31
Chemomab Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+13.97%USD 1.362026-07-24
1 month-8.82%USD 1.702026-07-01
3 month-3.62%USD 1.612026-05-01
Year to date-6.06%USD 1.652025-12-31
1 year-63.79%USD 4.282025-07-31
3 year-69.73%USD 5.122023-08-01
5 year-97.67%USD 66.522021-07-30
Since inception-99.35%USD 236.002021-03-17

Chemomab Therapeutics Financials at a Glance

Market Cap

$11.16MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$7.46M

EPS (TTM)

-$1.11

P/E Ratio

-1.40

Dividend

$0.00

Beta (Volatility)

1.10 (Average)

Price

$1.55

Volume

29,971

Open

$1.56

Previous Close

$1.55

Daily Range

$1.48 - $1.58

52-Week Range

$1.35 - $4.20

Estimated Earnings Date

Aug 13, 2026

CMMB News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Chemomab Therapeutics

Chemomab Therapeutics Ltd. operates as a clinical-stage biotech company. It discovers and develops therapeutics for conditions with unmet need that involve Inflammation and fibrosis. The company was founded by Adi Mor on September 22, 2011 and is headquartered in Tel Aviv, Israel.

Industry

Biotechnology

Sector

Health Care

Employees

12

CEO

Adi Mor, PhD

Website

www.chemomab.com

Headquarters

Tel Aviv, TA 6158002, IL

CMMB Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-67.85%

Return on Capital

-77.57%

Return on Assets

-63.15%

Earnings Yield

-71.43%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$11.16MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

7.20M

Volume

29.97K

Avg. Volume

128.41K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$7.94M

EBITDA

-$7.88M

Operating Cash Flow

-$11.22M

Capital Expenditure

-$3.03K

Free Cash Flow

-$11.22M

Cash & ST Invst.

$8.04M

Total Debt

$0.00

Chemomab Therapeutics Performance Analysis

Chemomab Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Chemomab Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Chemomab Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -9.68101.5%
20232023-12-31USD -8.22-15.0%
20242024-12-31USD -3.12-62.0%
20252025-12-31USD -1.42-54.5%
Chemomab Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3037.9%
Q32025-09-3021.7%
Q42025-12-3114.9%
Q12026-03-318.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$11.16MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$930.05K

N/A

Employees

12

N/A

Net Income

-$1.77M

+46.6%

EBITDA

-$1.83M

+47.2%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$8.04M

-23.9%

Total Debt

$0.00

-100.0%

Accounts Receivable

$3.43M

+169.3%

Inventory

$0.00

N/A

Long Term Debt

$0.00

-100.0%

Short Term Debt

$0.00

-100.0%

Return on Assets

-63.15%

N/A

Return on Invested Capital

-74.26%

N/A

Free Cash Flow

$0.00

N/A

Operating Cash Flow

$0.00

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BIVIBioVie Inc.
$1.52+6.29%
GLMDGalmed Pharmaceuticals Ltd.
$0.62+3.67%
INMInMed Pharmaceuticals Inc.
$1.47-2.00%
KZIAKazia Therapeutics Ltd ADR
$12.62-1.56%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$200.75+0.03%
AAPLApple
$308.91-0.07%
AMZNAmazon
$271.58+0.15%
INTCIntel
$90.20-0.01%

Questions About CMMB

What is the current price of Chemomab Therapeutics?

Chemomab Therapeutics is trading at $1.55 per share.

What is the 52-week range for Chemomab Therapeutics?

Over the past 52 weeks, Chemomab Therapeutics has traded between $1.35 and $4.20.

How much debt does Chemomab Therapeutics have?

As of the most recent reporting period, Chemomab Therapeutics reported total debt of $0.00.

How much cash does Chemomab Therapeutics have on hand?

Chemomab Therapeutics reported $5.91M in cash and cash equivalents in its most recent financial results.

What is Chemomab Therapeutics’s dividend yield?

Chemomab Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services